281 related articles for article (PubMed ID: 35031874)
1. Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options.
Bixio R; Bertelle D; Pistillo F; Pedrollo E; Carletto A; Rossini M; Viapiana O
Clin Rheumatol; 2022 Apr; 41(4):1247-1254. PubMed ID: 35031874
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab-induced myasthenia gravis: case-based review.
Pelechas E; Memi T; Markatseli TE; Voulgari PV; Drosos AA
Rheumatol Int; 2020 Nov; 40(11):1891-1894. PubMed ID: 32322981
[TBL] [Abstract][Full Text] [Related]
3. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis.
Bucknall RC; Dixon A St J; Glick EN; Woodland J; Zutshi DW
Br Med J; 1975 Mar; 1(5958):600-2. PubMed ID: 1125624
[TBL] [Abstract][Full Text] [Related]
4. [A case of myasthenia gravis following sarcoidosis and rheumatoid arthritis].
Sawada J; Asanome A; Endo H; Saito T; Katayama T; Hasebe N
Rinsho Shinkeigaku; 2013; 53(5):351-5. PubMed ID: 23719982
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate treatment in myasthenia gravis.
Karaahmet OZ; Bal A; Dulgeroglu D; Bahceci HK; Cakcı A
J Clin Neuromuscul Dis; 2014 Dec; 16(2):106-7. PubMed ID: 25415524
[No Abstract] [Full Text] [Related]
6. Rheumatoid arthritis and ocular myasthenia gravis: Effectiveness of rituximab in the management of these two diseases.
Novella-Navarro M; Salvatierra-Ossorio J; Muñoz-Gómez MDM; Pavo-Blanco M
Reumatol Clin (Engl Ed); 2018; 14(3):179-180. PubMed ID: 28624374
[No Abstract] [Full Text] [Related]
7. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
9. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
10. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Fleischmann RM; Blanco R; Hall S; Thomson GTD; Van den Bosch FE; Zerbini C; Bessette L; Enejosa J; Li Y; Song Y; DeMasi R; Song IH
Ann Rheum Dis; 2021 Apr; 80(4):432-439. PubMed ID: 33148701
[TBL] [Abstract][Full Text] [Related]
11. Penicillamine-induced ocular myasthenia gravis in rheumatoid arthritis.
Liu GT; Bienfang DC
J Clin Neuroophthalmol; 1990 Sep; 10(3):201-5. PubMed ID: 2144538
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
13. [D-penicillamine-induced myasthenia gravis].
Frey RA; Keller F; Michel BA
Schweiz Med Wochenschr; 1994 May; 124(20):852-6. PubMed ID: 8209208
[TBL] [Abstract][Full Text] [Related]
14. Penicillamine-induced myasthenia gravis in a patient with rheumatoid arthritis. A case report.
Naidoo PD
S Afr Med J; 1981 Sep; 60(12):478. PubMed ID: 7280897
[TBL] [Abstract][Full Text] [Related]
15. [Janus kinase inhibitors].
Witte T
Z Rheumatol; 2022 Mar; 81(2):94-99. PubMed ID: 34820733
[TBL] [Abstract][Full Text] [Related]
16. D-penicillamine-induced myasthenia gravis: diagnosis obscured by coexisting chronic obstructive pulmonary disease.
Adelman HM; Winters PR; Mahan CS; Wallach PM
Am J Med Sci; 1995 Apr; 309(4):191-3. PubMed ID: 7900739
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
19. [Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)].
Alten R; Nitschmann S
Internist (Berl); 2017 Dec; 58(12):1341-1344. PubMed ID: 29119202
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
